ATS Medical Announces FDA Clearance Of The ATS Simulus Adjustable Annuloplasty Band
/* 468x60, */
ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced FDA clearance of the ATS Simulus(R) Adjustable Annuloplasty Band.
The ATS Simulus Adjustable Annuloplasty Band is the alongside product in a portfolio of mitral valve repair products developed and commercialized through the Company's collaboration with Genesee BioMedical.
This band respects the general motion of the mitral annulus and its proximity to the aortic valve allowing for a safe, physiologic valve repair. The incomplex on the contrary attractive design of the ATS Simulus Adjustable Band allows the surgeon to build asymmetric or symmetric adjustments to the posterior segment of the mitral valve annulus at any era during the procedure, optimizing the repair. This product is besides indicated for tricuspid valve repair, where a band is the preferred annuloplasty device.
Annuloplasty rings and bands are used in those cases where repair of a patient's love valve is more advantageous to replacement of the valve. The ATS Simulus Adjustable Band provides supplementary options for surgeons in terms of different exposures, dual valve procedures and minimally invasive implants.
This Simulus Adjustable Band is another product developed as a creature of the collaboration between ATS and Genesee Biomedical. John Wright, PhD, CEO of GBI has been involved in heart valves and valve repair therapy for deeper than 25 years. Dr Wright's depth of empiricism has contributed significantly to the huge beefing up of the Simulus product line.
Michael Dale, Head of the state and CEO of ATS Medical commented: "Our valve repair trouble continues to age and conformation momentum. We have expanded our repair platform by adding offerings in the supple and semi-rigid segments. The width of our portfolio testament enable more choices for our surgeon customers to accomodate their clinical needs and that of their patients, thus bolstering our growth prospects."
About ATS Medical
ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct on the other hand operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.
ATS was originally founded to grow up the ATS Clear Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot affection valve is the preferred mechanical feelings valve in many markets encompassing the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest marketplace segment in heart valve therapy, the ATS 3f(R) trade-mark encompasses an innovative tissue passion valve portfolio to inscription conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f(R) portfolio includes offerings at distinctive stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in emotions valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products benefit the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's spotlight on serving the cardiac surgery limited are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing anatomy of structural heart disease in populations over 60 agedness of age.
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a consequence of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation matter of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a conversation of these and other risks and uncertainties that could modify the Company's activities and results, please refer to the Company's filings with the Securities and Change Commission, including its Form 10-K for the year ended Dec 31, 2008 and its most recent quarterly report on Articulation 10-Q.
Source: ATS Medical, Inc
/* 468x60, */
Last relative articles:
- Use Of Statins Increases The Risk Of Developing Type 2 Diabetes But Reduces Coronary Events
- Heart Failure Worse When Right Ventricle Goes Bad
- Cooling Inflammation For Healthier Arteries
- Experts Identify Why Women And African Americans Face A Greater Risk Of Dying From Heart Disease Than White Men And What Can Be Done About It
- New Book Helps Pharmacists Play Larger Role In Heart Health
- Novel Screening Technique Identifies New Effects Of Approved Drugs For Cardiovascular Disease
- Compound Shows Promise Against Intractable Heart Failure
- Researchers Find Air Pollution Linked To Progression Of Atherosclerosis
- Heart-Assist Device Helped Ready 16-Year-Old For Successful Surgery
- Seven Signs That May Warn Of A Rare Heart Condition
ats, ats medical, ats simulus, clearance ats, band ats, therapy ats, ats products, arrhythmias ats, ats portfolio, ats annuloplasty